Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its insulin production site in Frankfurt, Germany.
法国制药公司赛诺菲安万特将投入13-15亿欧元（14-16亿美元）提升其在德国法兰克福的胰岛素生产基地。
The site in Frankfurt's Hoechst district is known for producing the company's insulin brand, Lantus.
法兰克福Hoechst区的该基地以生产公司的胰岛素品牌Lantus而闻名。
Also Read: Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M.
夏威夷法院裁定反对百时美施贵宝和赛诺菲血栓药物案，增加赔偿金额至9.16亿美元。
This move comes after initial plans to shift Lantus production to France were reconsidered.
此举是在最初将Lantus的生产转移到法国的计划被重新考虑之后。
The decision to invest in the Frankfurt site represents a significant victory for Germany's healthcare sector.
投资法兰克福基地的决定对德国的医疗保健行业来说是一个重大胜利。
Germany's ruling coalition has been actively working to attract healthcare investments. In February, Daiichi Sankyo announced plans to spend around 1 billion euros to advance its precision cancer drug work near Munich.
德国执政联盟一直在积极争取吸引医疗保健投资。今年2月，第一三共(Daiichi Sankyo)宣布计划在慕尼黑附近投资约10亿欧元推进其精准癌症药物工作。
Eli Lilly (NYSE:LLY) also committed 2.3 billion euros last November to produce obesity and diabetes medications in Germany.
去年11月，Eli Lilly (美国纽约证券交易所代码LLY)也承诺在德国生产肥胖和糖尿病药物的投资为23亿欧元。
Sanofi's investment is expected to bolster its production capabilities and reinforce its commitment to maintaining a strong manufacturing presence in Germany.
赛诺菲的投资预计将增强其生产能力，并加强其维持德国强大制造业存在的承诺
Reuters noted that the upgrade will likely enhance Lantus's supply chain stability and support Sanofi's long-term strategic goals.
路透社指出，升级将很可能增强Lantus的供应链稳定性，并支持赛诺菲的长期战略目标。
In May, Sanofi announced an investment of more than €1 billion to create new bioproduction capacity at its French sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime), and Lyon Gerland (Rhône).
今年5月，赛诺菲宣布投资超过10亿欧元，在其法国位于瓦尔德马恩(Vitry-sur-Seine)、特雷(Seine-Maritime)和里昂杰兰(Rhône)的现有站点创造新的生物生产能力。
- Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC.
- 赛诺菲寻求出售价值200亿美元的止痛贴膏业务：可能的竞购者包括兴业、PAI Partners、黑石和CVC。
Price Action: At the last check on Monday, SNY shares were up 1.96% at $49.47.
股价表现：在周一最后一次查询时，赛诺菲股票上涨1.96%，报49.47美元。
Image by HJBC via Shutterstock
图像来自Shutterstock用户HJBC。